Navigation Links
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
Date:3/19/2013

CRANBURY, N.J., March 19, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/472,914 (the '914 application).  The application includes composition of matter claims on two of Palatin's most advanced melanocortin receptor-1 specific peptides.

Palatin is conducting in vitro and animal in vivo studies with the peptides claimed in the allowed patent and with related peptides.  Proposed indications under study include dermatologic indications such as vitiligo and erythropoietic protoporphyria, inflammatory bowel disease, ocular indications such as uveitis and dry eye, and nephritis and other kidney conditions.  Palatin plans to designate an initial clinical lead peptide candidate in the first half of 2013 and start toxicology and other preclinical studies preparatory to filing an Investigational New Drug Application with the U.S. Food and Drug Administration.

The peptides claimed in the '914 application are highly specific for the melanocortin-1 receptor, with sub-nanomolar affinity binding and EC50 functional values.  The peptides are also highly selective for the melanocortin-1 receptor, with greater than one thousand times the affinity for the melanocortin-1 receptor than for the melanocortin-4 or melanocortin-3 receptors.

"We are excited by the potential of our novel melanocortin receptor-1 peptides," stated Carl Spana , Ph.D., President and CEO of Palatin. "There are a number of significant unmet medical needs for which our highly specific and selective peptides can potentially provide new therapies."

'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Patient Safety Technologies Reports Fourth Quarter And Fiscal 2012 Results
3. Medbox Acquires 50% of MedVend and its Patented Technologies
4. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
5. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
6. Xyntek-Antares & ESS Technologies to Unveil New Ultra Compact TaskMate(R) Robotic Case Erector / Loader with Track & Trace at Interphex 2013
7. Cylene Pharmaceuticals and TetraGene Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
8. Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc.
9. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
10. Particle Sciences and NETZSCH Premier Technologies Enter into Collaboration
11. Animas Development of a First-Generation Closed Loop Insulin Delivery System Progresses With Data Presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... fiscal third quarter 2015 after the market close on ... will also host a conference call for investors on ... (10:00 a.m. Eastern Time). Investors may access the live ...
(Date:8/3/2015)... and MINNEAPOLIS , ... BSX ) has become a significant shareholder and ... representative for Preventice Solutions for cardiology-related diagnostic and ... an important strategic milestone for Preventice Solutions," said ... Strategy Officer, co CEO, Preventice Solutions.  "We are ...
(Date:8/3/2015)... 3, 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO ... for the quarter ended June 30, 2015. All comparisons, unless ... Second Quarter 2015 Highlights include: ... $266 million , Total prescriptions dispensed of 234,000, an ... 5.5% , Adjusted EBITDA of $22.7 million, an increase ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2Boston Scientific Announces Equity Investment And Sales Cooperation Agreement With Preventice Solutions 2Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... Jennerex,Inc. (San Francisco, CA and Ottawa, Ontario), and ... of the first five patients in a,Phase 2 primary ... JX-594. No significant toxicities were reported, and enrollment of,patients ... The Phase 2 trial involves treatment of patients ...
... Pulmo BioTech Inc. has completed a dual listing. The ... (symbol PBO) in addition to the OTC BB (OTC ... role in the future development and financing of the ... the United States and Canada" - Garry McCann, CEO ...
Cached Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 2Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... analysis for executives and technology professionals in healthcare and technology markets, today announced ... the Department of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related ...
(Date:8/3/2015)... ... August 04, 2015 , ... Approved ... extensive line up of live courses for the month of August. , Physical ... individually or by purchasing a Physical Therapy Flex package. Flex packages allow ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Putnam counties. As a family owned and operated business, Zeiter’s Septic has ... They are a leader in septic installations because of their continued training and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Since 1978, the number ... according to a new publication released today by the AAMC (Association of American Medical ... graduates over the past three decades, the number of black male applicants to medical ...
(Date:8/3/2015)... ... ... According to an opinion piece published July 28 by the Washington Post, the ... weight loss may not be accurate. While this system may work for some people, the ... – based both on the individual and at what point that person is in their ...
Breaking Medicine News(10 mins):Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2
... of Internal Medicine journal, Obese or overweight Chinese individuals ... developing tuberculosis than those at a normal weight. ... undernutrition in both developed and developing countries. In addition, ... a wide range of chronic degenerative conditions, notably, diabetes ...
... University of Washington shows that the work intended for ... economy . ,The research was conducted by a ... Hagopian, professor in the School of Public Health and ... Initiative; and Sally Weatherford, finance and administration director of ...
... guitarist Kevin Eubanks have won the 'World's Sexiest Vegetarians' title at ... new to the title, for she won the tag in 2005 ... for NBC's 'Tonight Show' band leader Eubanks, who bagged votes due ... for the 49-year-old and 'bring honour' to the show. ...
... researchers identify cost-effective treatment for drug-resistant typhoid. Researchers ... may be more effective at treating typhoid fever ... Organisation. ,Enteric fever, of which typhoid fever ... affecting the developing world, where sanitary conditions remain poor. ...
... have found that umbilical cord blood might safely preserve insulin ... ,The study was conducted by a team of ... Florida. ,As part of the study, researchers identified ... their umbilical cord blood at birth, and gave seven patients ...
... study published in the Journal of the National Cancer ... cancers is increasing, but this finding is likely ... Deirdre Cronin-Fenton, Ph.D., of Aarhus University Hospital in Denmark, ... Md., found that the increase in some early stage ...
Cached Medicine News:Health News:Obesity is Related to Lower Tuberculosis Risk 2Health News:Global Health Enriching the States Economy 2Health News:Gatifloxacin Very Effective for Typhoid Treatment 2
... ring pessary, available in nine ... support, is a very common ... second degree prolapse. The Ring ... used on an accompanying cystocele. ...
The Capio CL Transvaginal Suture Capturing Device allows for a transvaginal suture fixation to Cooper's Ligament for sling procedures...
... SPARC™ Sling System utilizes a suprapubic ... incontinence due to urethral hypermobility and/or ... two curved, narrow-diameter needles and a ... suture that allows for intra-operative tension ...
... technology marries with the well-researched ... sling, for exceptional resultsby design. ... and host, reduces the potential ... or erosion and provides secure ...
Medicine Products: